Drug intelligence / Profile preview

flopyramide [18F]

Development stage
Unknown
Lead developer
China Isotope & Radiation Corporation
Modality
Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration
Intravenous
01

Overview

Flopyramide [18F] is a fluorine-18 labeled radiopharmaceutical developed by Atom Hi-Tech, a subsidiary of China Isotope & Radiation Corporation, for use as a positron emission tomography (PET) imaging agent. It is specifically designed to target melanin, a pigment that is highly concentrated in melanoma cells. As a picolinamide derivative, flopyramide [18F] exhibits high affinity and specificity for melanin, enabling the sensitive detection of both primary melanoma and metastatic lesions, including those in the lymph nodes and distant organs. The drug is currently in late-stage clinical development (Phase 3) in China, aiming to provide a more accurate diagnostic tool for the staging and monitoring of melanoma compared to conventional tracers like [18F]FDG, which can have lower specificity in certain inflammatory contexts.

Other names
18F-flopyramide[18F]flopyramide6-[18F]fluoro-N-[2-(diethylamino)ethyl]picolinamide18F-flopyramide injection

Beyond the preview

Go deeper on flopyramide [18F].

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on flopyramide [18F].

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call